← Leaderboards
John Finn
Trius Therapeutics, Inc.
$3,924,166
Attributed
$3,924,166
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.6M · FY2006–13$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$3,924,166 · 2
By mechanism
N01$3,624,974 · 1
R43$299,192 · 1
Top collaborators
No co-investigators on record.
Most similar at Trius Therapeutics, Inc.
Same institution · by research overlap
- Mark Alan Stidham$1,205,225
- Mark A. Stidham$8,680,866
Others in their field
Top investigators on “Advanced Development”
- David Heimbrook · Leidos Biomedical Research, Inc.$625,894,719
- Bambra Strokes · Ppd Development Lp$526,656,217
- Leonard Freedman · Leidos Biomedical Research, Inc.$378,174,673
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$331,630,794
- David H Reitze · University Of Florida$318,606,363
- Albert Lazzarini · California Institute Of Technology$317,303,333
Research focus
Advanced DevelopmentBacterial Drug ResistanceBiodefenseEmerging Communicable DiseasesPathogenPharmaceutical PreparationsPre-ClinicalProduct DevelopmentResearch And DevelopmentResistanceSupport ContractsTherapeutic Development